{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/balanitis/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"2fc17559-2630-5868-aeda-16c7394d8223","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field ee01da49-c317-4078-a5e3-566182d81f5e --><h2>Changes</h2><!-- end field ee01da49-c317-4078-a5e3-566182d81f5e -->","summary":null,"htmlStringContent":"<!-- begin item efc8e9cc-1c5a-4ecb-91ec-c27f334bb297 --><!-- begin field da0f8beb-a1ae-47d2-b269-4863fcb6423f --><p><strong>October 2018 </strong>— minor update. Adverse effects updated within prescribing information - metronidazole. </p><p><strong>January to February 2018</strong> — reviewed. A literature search was conducted in January 2018 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone minor restructuring. A section on Complications has been added to the Background information section. A section on Differential diagnosis has been added to the Diagnosis section. The management recommendations have been updated in line with the current literature. The Prescribing Information section has been updated and expanded in line with current CKS style.</p><!-- end field da0f8beb-a1ae-47d2-b269-4863fcb6423f --><!-- end item efc8e9cc-1c5a-4ecb-91ec-c27f334bb297 -->","topic":{"id":"4da8d9db-f350-588f-83e8-f5efc3335305","topicId":"eb6c6cd9-3331-4790-a1f9-a11ed643b2b0","topicName":"Balanitis","slug":"balanitis","lastRevised":"Last revised in October 2018","chapters":[{"id":"cf843687-5035-5956-aa14-3d8bacbd404f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"41d01ca1-763c-529e-8026-28dd85d36b16","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b9dae5ef-34a6-57ed-bf21-9b9543370ecd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2fc17559-2630-5868-aeda-16c7394d8223","slug":"changes","fullItemName":"Changes"},{"id":"699e0434-3685-5acc-9956-84bc269b6ae0","slug":"update","fullItemName":"Update"}]},{"id":"e0b4a9d5-30c1-589c-b52c-49a537ed88cf","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"045bf9d9-1913-57d7-85ac-7dd14d9a6ad1","slug":"goals","fullItemName":"Goals"},{"id":"9242a4e0-3dd3-598a-8015-c1fd35c8ae24","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8d94eba3-36ae-5c38-b3bd-c6fe5a1d1122","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9c3fec0e-6d36-590b-a67a-9fde96b588b6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"dd19254a-f9ef-5cd1-af7b-f5226c2474da","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5cc7acd3-6e1c-5b23-9f58-aa1a50f67faa","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"10c99e35-8476-5d3d-a309-c80fc5ed5fa7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e615c22a-91ed-5f2c-8d1b-657c4409d5ff","slug":"definition","fullItemName":"Definition"},{"id":"93cf765a-7e94-5ba7-bc6c-d001406aa393","slug":"causes","fullItemName":"Causes"},{"id":"8f5ac951-0e46-5c89-9a50-27eb3f65076f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"feeb11e3-9d66-5d96-a507-c526af44a7f0","slug":"complications","fullItemName":"Complications"}]},{"id":"fb758dfb-b24b-5875-9570-5d6b29ad0606","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7f4b11b8-626e-56eb-9a8d-5aafbb365797","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"e0d6dde7-d713-5601-94f9-9a443f7c7cb3","slug":"assessment","fullItemName":"Assessment"},{"id":"a1bd5ccf-b828-59e7-893c-ab9d9e755750","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"de355ac0-0522-5d92-a913-4694aa861fd7","fullItemName":"Management","slug":"management","subChapters":[{"id":"bd1e001e-c6a9-5d54-88ca-ce4a56b46edd","slug":"balanitis-children","fullItemName":"Scenario: Balanitis - children"},{"id":"44e5d982-e2af-5996-ab20-fcc33b89adf1","slug":"balanitis-adults","fullItemName":"Scenario: Balanitis - adults"}]},{"id":"3fdc0cf3-e98c-5a04-9525-c21e93db6dad","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"7db80726-7da5-5db6-85b2-e6a211cd3278","slug":"topical-imidazoles","fullItemName":"Topical imidazoles"},{"id":"ad41f201-03ec-5da9-ac6a-1902fa6cad6c","slug":"oral-fluconazole","fullItemName":"Oral fluconazole"},{"id":"29db55e2-6292-57cc-bb96-e0331bea331b","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"41cf5c1f-073b-55f6-bca1-f483e1e31783","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"e2c0e955-b610-5ee0-83a7-020247e8d2e3","slug":"metronidazole","fullItemName":"Metronidazole"}]},{"id":"8384c8ca-522a-546a-971b-71a12dc40ba9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1946dc01-8848-5119-a228-39e16c9c2fee","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a80a505e-c0ca-5472-966a-cfb4d225c502","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f260f355-769f-5d83-8c42-f5b606d7cab7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bedff117-4d2b-5b3b-ae77-431100374dfe","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ccf2a0ba-1a8a-5d6c-829c-a90817d3a0cb","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c09916ae-40e4-5285-8ce4-a0995eb5225b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"fcdbbdd1-c423-5b0c-b610-1ba72cc625c9","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b9dae5ef-34a6-57ed-bf21-9b9543370ecd","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"905ef730-c3a2-5248-b713-2fde1005de2e","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 184a09ac-0549-4f30-807c-d719ec97540e --><h3>Previous changes</h3><!-- end field 184a09ac-0549-4f30-807c-d719ec97540e -->","summary":null,"htmlStringContent":"<!-- begin item 79a9c946-6126-45e1-b502-4d3f2fb5948e --><!-- begin field c82e7514-836a-4109-b4b4-c89e547cd271 --><p><strong>July 2015 </strong>— minor update. The information on the concurrent use of clarithromycin or erythromycin with statins has been clarified.</p><p><strong>January 2014 </strong>— minor update. Text amended to include information from the manufacturer's Summary of Product Characteristics (SPC) regarding how much clotrimazole to apply to the skin (SPC, 2014).</p><p><strong>August 2013 </strong>— reviewed. A literature search was conducted in July 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No major changes to recommendations have been made.</p><p><strong>August 2010 </strong>— minor update. Sulconazole 1% cream (Exelderm<sup>®</sup>) has been discontinued. The prescription has been removed. Issued in August 2010.</p><p><strong>February to June 2009 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There are no major changes to the recommendations.</p><p><strong>December 2008 </strong>— correction to a typographical error in the <em>Overview of management </em>section. Issued in January 2009.</p><p><strong>August 2008 </strong>— minor update. Nystatin cream and ointment discontinued; prescriptions removed and text amended. Issued August 2008.</p><p><strong>July to September 2006 </strong>— reviewed. Validated in December 2006 and issued in January 2007.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>April 2005 </strong>— minor update. Tinaderm-M<sup>®</sup> cream (nystatin 100,000 units/g and tolnaftate 1% cream) has been discontinued. The prescription has been removed. Issued in April 2005.</p><p><strong>October 2003 </strong>— written. Validated in December 2003 and issued in February 2004.</p><!-- end field c82e7514-836a-4109-b4b4-c89e547cd271 --><!-- end item 79a9c946-6126-45e1-b502-4d3f2fb5948e -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}